Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia

References

• Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part 1: pharmacology, pharmacokinetics, and efficacy. Annals of Pharmacotherapy 1999; 33: 73–85
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003; 160: 1209–1222
   PubMed Web of Science ®Google Scholar
• Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal 2005; 172: 1703–1711
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 2002; 159: 103–108
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 2003; 160: 1125–1132
   PubMed Web of Science ®Google Scholar
• Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. British Journal of Psychiatry 2004; 184: 509–516
   PubMed Web of Science ®Google Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 2004; 30: 255–264
   PubMed Web of Science ®Google Scholar
• Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law 1986; 14: 105–122
   PubMedGoogle Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002; 40: 630–639
   PubMed Web of Science ®Google Scholar
• Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion 2005; 21: 2017–2028
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 2004; 14: 87–92
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001; 179: 290–299
   PubMed Web of Science ®Google Scholar
• Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741–773
   PubMed Web of Science ®Google Scholar
• Chue P, Llorca P-M, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Journal of Applied Research 2005; 5: 266–274
   Google Scholar
• Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63: 493–512
   PubMed Web of Science ®Google Scholar
• Kelleher JP, Centorrino F, Albert MJ, et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 2002; 16: 249–261
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 2003; 64: 1250–1257
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry 2004; 19: 219–225
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. International Journal of Neuropsychopharmacology 2005; 8: 427–438
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology 2004; 19: 241–249
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophrenia Research 2005; 77: 215–227
   PubMed Web of Science ®Google Scholar
• Eriksson L, Almqvist A, Mehnert A, et al. The use of institutional psychiatric care significantly decreases with long-acting risperidone. In: 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro-Psychopharmacology;, Juan-les-Pins, France, April, 21–242004
   Google Scholar
• Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety 2004; 13: 811–826
   PubMed Web of Science ®Google Scholar
• Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics 1993; 15: 917–926
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: APA 1994
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Lawless JF. Statistical Models and Methods for Lifetime Data. John Wiley & Sons, New York, NY 1982
   Google Scholar
• Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society Series B (Statistical Methodology) 1972; 34: 187–220
   Web of Science ®Google Scholar
• McNemar Q. Note on the sampling error of the difference between correlated proportions of percentages. Psychometrika 1947; 12: 153–157
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Economics and schizophrenia: the real cost. British Journal of Psychiatry Supplement 1994; 25: 18–21
   PubMedGoogle Scholar
• Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry 1999; 156: 863–868
   PubMed Web of Science ®Google Scholar
• Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatrica Scandinavica 2007; 116: 36–46
   PubMed Web of Science ®Google Scholar
• Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results and implications. American Journal of Managed Care 1997; 3: 873–877
   PubMed Web of Science ®Google Scholar
• Paton C, Okocha C. Risperidone long-acting injection: the first 50 patients. Psychiatric Bulletin 2004; 28: 12–14
   Google Scholar
• Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatrica Scandinavica 2006; 114: 14–20
   PubMed Web of Science ®Google Scholar
• Taylor D. Risperidone long-acting injection in practice—more questions than answers? Acta Psychiatrica Scandinavica 2006; 114: 1–2
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Scott Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine 2005; 353: 1209–1223
   PubMed Web of Science ®Google Scholar
• Edwards NC, Rupnow MFT, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics 2005; 23: 299–314
   PubMed Web of Science ®Google Scholar
• Ontario Case Costing Initiative. Available at: http://www.occp.com/ [last accessed 24 August 2007]
   Google Scholar
• Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics 1998; 14: 97–133
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics 2005; 23((Suppl. 1))62–74
   PubMedGoogle Scholar